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Introduction 
The isolation and successful culturing of human pluripotent stem cells over a decade ago has 
proven to be a truly revolutionary moment in modern scientific research.  We are now able to 
study and manipulate cells that are capable of differentiating into nearly every cell type present in 
the adult body.  Initial studies using embryonic stem cells (ESC) have led to development of 
methods to reprogram terminally differentiated cells into induced pluripotent stem cells (iPS).  
One such area of intrigue using these technologies is vascular development and how applying 
knowledge of the cells that make up this vital network can be used to improve the lives of those 
that suffer from maladies that afflict it.  The primary component of any vasculature system is the 
endothelial cell (EC) which constitutes the framework for every vessel that serves to deliver 
nutrients, important signaling molecules, and immune response capability to every cell in the 
body.  Interactions with other vasculature-associated cells (also known as mural cells) such as 
smooth muscle cells (SMC) and pericytes provide stable vessels that allow for consistent blood 
flow as well as invasion into the local tissue by immune cells.  While this process, known as 
vasculogenesis, is established during embryonic development, it is also undertaken when needed 
in adult tissues where it is referred to as angiogenesis.  Whether it is in response to injury or a 
result of tissue growth, the vascular system is dynamic in nature in order to meet the needs of the 
organism. 
 Characterization of mature endothelial cells can be accomplished by analysis of the 
expression of extracellular proteins or markers which, when taken together, can identify the 
endothelial phenotype.  While these markers can aid in identifying endothelial cells, they cannot 
do so individually as the majority are not expressed solely on ECs.  Most are required for vessel 
integrity and prevention of leakiness in the absence of inflammation while others provide 
essential enzymatic functions.  One of the most important and reliable markers used is platelet 
endothelial cell adhesion molecule 1 (PECAM1, also known as CD31).  This surface protein is 
involved in cell to cell interactions known as adherens junctions and is required for maintenance 
of the integrity of vessels.  It is, however, not specific to endothelial cells as it is also expressed 
on leukocytes and developing hematopoietic stem cells (HSC)
1
.  Another essential intercellular 
adhesion molecule involved in vessel stability for ECs is vascular endothelial cadherin (VE-
cadherin, also known as CD144).  Like CD31, CD144 is also expressed on a subset of 
hematopoietic cells during development which makes using it to identify distinctions between 
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early ECs and HSCs difficult
2
.  A third glycoprotein involved in cell to cell adhesion that is co-
expressed on ECs and HSCs is CD34.  Little is known about its exact function but like CD31 and 
CD144 it is expressed on early hematopoietic/vascular progenitors.  Intercellular adhesion 
molecule 2 (ICAM2, also known as CD102) is yet another important adhesion protein that is 
highly expressed on endothelial cells but can also be found on leukocytes and hematopoietic 
progenitors
3
.   The enzyme 5'-nucleotidase (5'-NT, also known as CD73) is expressed on the 
plasma membrane of ECs and is involved in the metabolism of extracellular adenosine 
monophosphate (AMP) to adenosine as well as leukocyte trafficking in vessels
4
.  This enzyme is 
also reliably expressed on mesenchymal stem cells (MSC) which is not surprising given the close 
relationship between this type of cell and ECs
5
.  Melanoma cell adhesion molecule (MCAM, also 
known as CD146) is also expressed on both MSCs and ECs and may be involved in leukocyte 
extravasation
6
.  While identification of these markers on a cell surface are useful in determination 
of an endothelial phenotype, they must be used in conjunction with functional assays and gene 
expression profiles in order to conclusively characterize differentiated ECs.          
 During embryonic development, endothelial cells and the vascular cells that they interact 
with are differentiated from mesoderm precursors that are capable of committing to the 
hematopoietic lineage.  Immediate precursors to endothelial cells are known as angioblasts and 
first arise in humans within the blood islands of day 7-13.5 post-conception embryos and are also 
involved in later hematopoietic development
7
.  These cells are also capable of differentiation into 
smooth muscle cells as the vascular system matures in the developing embryo
8
.  Early cells that 
express endothelial cell surface markers that give rise to initial hematopoietic precursors are 
known as the hemogenic endothelium (or hemangioblasts) and are essential for proper 
hematopoietic system generation
9
.  Given the shared precursor of both endothelial and 
hematopoietic cells, in vitro differentiation of both can be done under similar conditions.  Specific 
protocols for endothelial generation have been well established
10,11
 but the differences between 
mature cells and endothelial progenitors make isolation of pure populations difficult although not 
impossible.  We sought to establish our own protocol that would provide more directed 
endothelial differentiation and increase the overall yield of differentiated cells.  Our initial 
method of differentiation involved co-culture of embryonic and induced pluripotent stem cells 
with mouse stromal cells that are able to support hematopoietic commitment.  This method also 
utilized a media that contained fetal bovine serum (FBS) which did not specifically induce 
differentiation of any one specific cell type.  This lack of specificity resulted in low overall yields 
of cells that expressed EC-associated surface proteins which were used to identify and isolate the 
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desired populations.  The majority of these cultures became stromal in nature and were 
accompanied by extensive extracellular matrix proteins which made dissociation into a single cell 
solution difficult.  In order to improve upon this, we turned to a previously established system for 
hematopoietic development through the use of a defined media in the absence of stromal feeder 
cells
12
.  Instead of co-culturing undifferentiated pluripotent cells with murine fibroblasts, this 
system utilizes formation of embryoid bodies (EB) in the absence of feeder cells along with a 
defined culture media.  Although this system requires more media components and is subject to 
its own issues of variability, it has proven to be beneficial by reducing the time needed for 
differentiation as well as honing the lineage commitment towards hematopoietic precursors.   In 
addition to refining the differentiation process, this system eliminated any xenobiological effects 
from growing human cells on mouse cells which is necessary for future development towards 
viable cell therapies in human patients.  Because this protocol was designed for definitive 
hematopoietic development, we needed to adjust it to suit our goals of endothelial differentiation.  
To this end, we modified the cytokine components and examined the use of small polypeptides 
and small molecule inhibitors in order to further enhance mature endothelial development. 
 The course of differentiation towards specific cell lineages is, for the most part, 
determined by temporal exposure of pluripotent cells to growth factors which induce signaling 
processes that influence the expression of lineage-specific genes.  The first of these lineage 
commitments that occur in the generation of endothelial cells is towards the mesoderm germ layer 
as opposed to ectoderm or endoderm.  In vitro studies have shown that the presence of bone 
morphogenic protein 4 (BMP4), vascular endothelial growth factor (VEGF), and basic fibroblast 
growth factor (bFGF) are able to support development of a progenitor population from 
mesodermal cells which are capable of becoming hematopoietic, endothelial, mesenchymal, 
cardiomyocyte, and smooth muscle cells
13
.  Each of these cytokines plays an important temporal 
role as BMP4 is essential for efficient mesoderm formation, bFGF for development of 
hemangioblasts, and VEGF (along with thrombopoietin) for hematopoietic commitment
14
.  While 
these cytokines are certainly present in the FBS used in stromal cell co-culture differentiation, the 
availability of other cytokines that are involved in commitment to various other cell lineages 
reduced the efficiency of that process.  By limiting the differentiation media to only those 
components that are involved in efficient hemangioblast differentiation, we hypothesized that the 
efficiency of endothelial cell generation would be increased.   
  We have also examined the effects of inhibiting notch receptor signaling in order to 
further enhance endothelial commitment of differentiating cells.  Notch is an evolutionarily 
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conserved receptor that is involved in generating signals based on cell to cell interactions which 
help to define various differentiation processes
15
.  The ligands for notch, Delta-like (DLL) and 
Jagged (JAG), are expressed on the surface of neighboring cells which drives the cell to cell 
signaling complex.  It has been established that cells can express both ligand and receptor and the 
two are capable of acting in a cis manner to initiate the signaling process
16
.  Activation of notch 
results in cleavage of the intracellular domain (NICD) which subsequently interacts with other 
transcription factors in the nucleus in order to enhance the expression of notch target genes
17
.  
While this signaling pathway plays a role in multiple lineage commitment phases during 
development, our research has focused on the ability of notch to direct hemangioblast fate.  Along 
with the hedgehog transcription factor, notch signaling has been shown to be an important 
element of commitment to hematopoietic progenitors from the hemangioblast precursor
18
.  
Furthermore, inhibition of NICD cleavage by the γ-secretase inhibitor DAPT (N-[(3,5-
Difluorophenyl)acetyl]-L-alanyl-2-phenyl]glycine-1,1-dimethylethyl ester) has been shown to 
reduce hematopoietic development in hemangioblasts and enhance endothelial development in in 
vitro studies
19
.            
 Depending on the type of vessel they are a part of, endothelial cells in the mature 
vascular system can be arterial, venous, or lymphatic.  These designations are not arbitrary as 
each EC type has unique phenotypic and genotypic components which determine the functional 
ability of each in order to maintain the integrity of the vasculature.  In vitro studies have relied on 
the use of human umbilical arterial endothelial cells (HUAEC), venous endothelial cells 
(HUVEC), and lymphatic endothelial cells (HLEC) as standards for identifying the differences in 
phenotypes.Arteries and veins are essential for normal blood flow throughout the body while 
lymphatic vessels play an important role in trafficking of immune cells and lymph fluid.  The 
determination of which type an endothelial cell will become occurs early in development before 
the vasculature is fully formed and blood flow is initiated.  Early EC progenitors accumulate in a 
region called the intermediate cell mass (ICM) which is ventral to the notochord and between the 
somites
20
.  It is here (or possibly during migration) that these progenitors undergo arterial-venous 
specification as they form the dorsal aorta and posterior cardinal vein
21
.  One of the most 
important determinants of this specification is the expression of ephrin family proteins, 
specifically ephrin B2 (EPHB2) and its receptor ephrin B4 (EPHB4).  The presence of this 
receptor-ligand pair is not equally distributed as EPHB2 is more highly expressed on arterial cells 
whereas EPHB4 is more venous in nature.  A study using a mutant Ephb2-LacZ reporter mouse 
model has indeed shown that EPHB2 is restricted to developing arteries whereas EPHB4 is only 
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found in venous endothelial cells
22
.  This same model showed that while early vessel 
development was possible, progression to a mature vasculature was defeated by impaired 
interactions between arterial and venous vessels which resulted in embryonic lethality.  It is 
theorized that developing ECs have already committed to either arterial or venous identity prior to 
interactions between the two vessel types which would explain the delay in lethality in this mouse 
model.   
 Another defining component of arterial-venous specification is the aforementioned notch 
signaling pathway.  It has been established that Notch 1, Notch 4, and their ligands are restricted 
to arterial ECs and are absent from venous ECs
23
.  It has also been shown that mice heterozygous 
for the Notch ligand DLL4 have increased EPHB4 and reduced EPHB2 expression which results 
in a lack of arterial commitment by endothelial progenitors
24
.  Analysis of Notch expression 
during zebrafish development further elucidates its important role in arterial specification as loss 
of Notch decreases arterial marker expression as well as increases expression of venous markers 
on the dorsal aorta.  This condition also leads to vessel development defects primarily due to 
incomplete arterial-venous differentiation.  Conversely, increased Notch expression diminishes 
venous specification in the developing embryo
25
.  While mature vessel development is severely 
impacted by loss of Notch, this occurs after the formation of primary vessels which implies that it 
is not necessary for aggregation of hemangioblast precursors during initial vasculogenesis.  Also 
of note is that zebrafish lacking Notch show expression of some arterial-specific markers which 
provides evidence for upstream elements of Notch influencing the commitment to an arterial 
phenotype.  Downstream products of Notch signaling have been shown to be influential in 
expression of arterial specific genes.  Hairy/enhancer-of-split related with YRPW motif protein 
(HEY) and hairy/enhancer-of-split (HES) family proteins are transcription factors whose 
expression is dependent on Notch-mediated transcription.  Mice that are Hey1 and Hey2 deficient 
are embryonic lethal due to cardiovascular defects caused by improper arterial specification
26
.  
Similar experiments using Hes1 knockout mice showed reduced vascular remodeling and lack of 
arterial ECs in embryos
27
.  Inhibition of Notch in cultured cells can be performed without needing 
to generate mutant knockdowns or knockouts as small molecule drugs have been developed to 
disrupt the signaling pathway.  DAPT is a widely used inhibitor of γ-secretase activity which is 
required for cleavage of the intracellular portion of the Notch receptor
28
.  It has been used to 
examine the role of this enzyme in the formation of amyloid β-peptide plaques which are 
implicated in Alzheimer's disease as well as cancer development but has also shown usefulness 
for identifying the mechanisms of Notch function in cardiovascular development.  The 
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importance of the Notch signaling pathway is preserved in the mature vasculature as it is required 
for recruitment of smooth muscle cells and pericytes to interact with endothelial cells and form 
stable arterial vessels
29
. 
 In contrast to notch-dependent arterial specification, venous development requires 
transcriptional activation of specific genes by a unique transcription factor.  Chicken ovalbumin 
upstream promoter-transcription factor II (COUP-TFII) was identified as a mediator of venous 
identity and is expressed only in venous and not arterial ECs
30
.  Experiments with COUP-TFII 
knockout mice resulted in embryonic death due to severe hemorrhage and enlarged blood vessels 
as well as underdeveloped atria and malformed cardinal veins
31
.  In vitro experiments with 
targeted disruption of COUP-TFII in mouse vein ECs caused an upregulation of arterial specific 
genes EphB2, Jag1, Notch1, and neuropilin-1 (Nrp1) while ectopic expression in vivo results in 
fusion of arteries and veins which is similar to the findings of notch
-/-
 mice
32
.  It is theorized that 
COUP-TFII regulates venous identity by decreasing notch signaling which releases EphB4 and 
VEGFR3 (described later) from being repressed by it
30
.  A second, less understood mediator of 
venous identity is apelin (APLN), a polypeptide that activates the apelin receptor (APJ).  APJ has 
been shown to be essential for maturation and proper development of in vivo vascular networks
33
 
as well as hematopoiesis
34
.  Stimulation of APJ, a G-protein coupled receptor, activates a 
signaling pathway that enhances activation of myocyte enhancer factor 2 (MEF2) which has been 
shown to be essential for endothelial and cardiovascular development
35
.  Analysis of the 
developing retinal vasculature in mouse embryos has shown early expression of APJ on venous 
ECs which is not present on arterial ECs
36
.  APJ expression is maintained through maturation and 
is implicated in the induction of a hypotensive state in blood vessels due to increased nitric oxide 
(NO) production following activation
37
.  Apj
-/-
 mice also showed significant cardiac deficiencies 
due to the lack of Krüppel-like factor-2 (KLF2) expression
38
, an APJ-dependent regulator of 
cardiac development. 
 Arguably the most important growth factor for endothelial differentiation, growth, and 
survival is vascular endothelial growth factor (VEGF).  A secreted cytokine, VEGF has multiple 
isoforms (VEGF-A, VEGF-B, VEGF-C, VEGF-D and VEGF-E) which bind to different 
extracellular receptors which include fetal liver kinase-1 (Flk1, also known as VEGFR2), fms-
like tyrosine 1 (Flt1, also known as VEGFR1), fms-like tyrosine 4 (Flt4, also known as 
VEGFR3), and neuropilins 1 and 2 (NP1, NP2)
39
.  VEGFR1 acts as a negative regulator of 
vasculogenesis during embryonic development and has a high binding affinity for the VEGF-A 
isoform compared to VEGFR2 and VEGFR3
40
.  VEGF-B binds only to VEGFR1 while VEGF-C 
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and VEGF-D can bind to VEGFR2 and VEGFR3
41
.  The C and D isoforms have a strong affinity 
for VEGFR3 and are involved in the regulation of lymphangiogenesis, the development of 
lymphatic vessels.  Expression of VEGFR1 and VEGFR2 is not restricted to endothelial cells as 
the former is also found on osteoclasts, dendritic cells, pericytes and trophoblasts
42,43
 while the 
latter has been found to be expressed on neuronal cells, osteoblasts, pancreatic duct cells, 
megakaryocytes, and retinal progenitor cells
44
.  VEGFR2 has also been found on certain 
populations of circulating cells that co-express hematopoietic markers and are believed to be 
endothelial progenitor cells that are involved in neo-angiogenesis
45
.  Mice that are null for 
VEGFR1 are embryonic lethal and show disorganized blood vessels and EC overgrowth.  The 
ligand-binding domain, not the kinase domain, may be responsible for this effect by reducing the 
amount of free VEGF-A available to bind to VEGFR2 and deliver cell growth and proliferation 
signals
46
.  VEGFR2 is expressed highly on hemangioblasts so mouse models in which gene 
expression is inactivated are embryonic lethal due to undeveloped vasculature as well as 
diminished hematopoietic development
47
.  It is also upregulated during neo-angiogenesis in 
mature vessels on tip cells which are the lead of new sprouting vessels.  While VEGFR3 is 
limited to lymphatic endothelial cells in the mature vasculature, it has been shown to be essential 
during development as gene inactivation leads to embryonic lethality in mice due to improper 
vessel remodeling
48
.  The variability of VEGF receptor signaling shows that it is an intricate 
system of regulated and temporal expression involved in the development of a functional 
vasculature. 
 The signaling receptors described are only the initial elements of the signaling pathways 
that ultimately determine the arterial, venous, or lymphatic fate of endothelial precursors.  While 
Notch activation has been implicated as a primary driver of arterial specification, its signaling can 
be augmented by other kinases present.  VEGFR activation has been shown to activate two 
downstream effectors, extracellular signal-regulated kinase (ERK) and phosphatidylinositol-3 
kinase (PI3K) which have opposite and competing effects on cell fate.  Chemical screens using a 
zebrafish hey2 ortholog mutant model, named gridlock (grl), have been able to identify small 
molecule inhibitors that target these kinases and indentify their role in arterial-venous 
specification
49
.  Inhibition of ERK or upstream signaling molecules results in decreased arterial 
cell differentiation and malformation of the dorsal aorta whereas constitutive PI3K/AKT 
signaling induces more commitment to the venous fate by hemangioblasts.  It is thought that 
PI3K/AKT activity is capable of disrupting ERK signaling in some as yet undefined manner.  
Interestingly, some studies done in vitro suggest that PI3K activates notch and Dll4 which is in 
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contrast to the in vivo findings
50,51
.  Application of GS4012, a flavone small molecule, to the grl 
mutant zebrafish model rescued the normal vascular development by activation of the VEGF 
signaling pathway
52
.  A structurally dissimilar molecule identified in chemical screens, GS4898, 
achieved the same phenotype rescue by inhibiting a downstream effector of the PI3K signaling 
pathway, AKT
53
.  To this end, various other inhibitors of PI3K signaling have been identified 
including wortmannin,  LY294002
54
, and PI-103 which is also capable of inhibiting the 
mammalian target of rapamycin (mTOR), a kinase involved in the PI3K pathway
55
.  Investigation 
of these pathways have revealed influences on a variety of protein expression patterns in different 
cell types and their functional consequences.  Many studies have examined the use of PI3K 
inhibitors for treatment of various cancers, some by affecting the ability of solid tumors to 
vascularize their tissue
56
.  From this research, a relationship between the chemokine receptor 
CXCR4 and PI3K signaling has been established albeit with limited focus on how this interaction 
functions in endothelial cells.  CXCR4 is expressed on a variety of cell types and along with its 
ligand, stromal-derived-factor-1 (SDF-1, also known as CXCL12), is involved in chemotaxis and 
homing in hematopoietic cells
57
.  Mice deficient for CXCR4 or SDF-1 show an inability to form 
arterial networks in the developing small intestine while the venous capillaries remained intact, 
potentially identifying a role for the receptor and its ligand in angiogenesis
58
.  It has also been 
established that ECs expressing CXCR4 at high levels are more effective during repair of 
ischemic limbs in mice
59
.  An effective positive regulator of CXCR4 expression in various cell 
types is cyclic adenosine monophosphate (cAMP)
60,61
.  Activation of signaling pathways 
involving this small molecule have also been implicated in upregulation of notch and subsequent 
arterial specification via VEGF signaling enhancement
62,63
.           
 According to the CDC, roughly 600,000 people die of cardiovascular disease each year 
which represents about one in every four deaths
64
.  In addition to the human cost of this type of 
disease, it is estimated that it costs the United States $108.9 billion in healthcare costs and lost 
productivity
65
.  It has become abundantly clear that traditional treatments will need to be 
augmented with newer technologies to address the severity of this problem.  Ongoing research 
into the efficacy of cellular therapies has benefitted greatly from the ability to generate vascular 
cells from embryonic or induced pluripotent stem cells.  For this reason we investigated the effect 
of transplantation of our endothelial and smooth muscle cells into mouse and pig ischemic models 
to analyze their ability to improve the repair of the damaged tissue and provide therapeutic 
benefit.  This was done in collaboration with Dr. Jay Zhang's laboratory at the University of 
Minnesota who performed the actual surgeries and post-surgical analysis.  While this type of 
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therapy has shown promising results in other investigations
66
, we sought to determine the 
potential benefits of using a fibrin-based patch in conjunction with delivery of the cells to the 
ischemic site.  Given the dynamic nature of the surface of the heart, the patch was expected to 
provide stability for the transplanted cells at the ischemic site and improve interaction with the 
endogenous tissue.  This collaboration has resulted in multiple publications that have 
demonstrated the therapeutic benefit of this system as well as providing an in vivo model with 
which to determine the functional efficacy of our ES/iPS-derived ECs and SMCs
67-69
. 
 The primary goals of our research have been twofold: first, we sought to optimize our 
established differentiation protocol in order to enhance the development of mature endothelial 
cells that are capable of being cultured for multiple passages while maintaining endothelial 
functionality and phenotype.  Generation of ECs from pluripotent stem cells is not a novel 
process, but discussions with others in this area of research have revealed the difficulty in 
growing cells that are able to mimic primary endothelial cells in extended culture conditions.    
We hypothesized that, based on established research, the treatment of undifferentiated cells with 
cytokines known to induce hemangioblast differentiation at temporally-sensitive intervals would 
not only increase the yield of mature ECs but also allow for longer culturing before replicative 
senescence or transformation to a more fibroblast-like phenotype.  Our second goal was to 
determine if the ECs generated were genotypically and phenotypically similar to primary arterial, 
venous, or lymphatic endothelial cells.  In addition to this, we sought to identify methods that 
could potentially influence this fate determination in developed ECs towards a more arterial 
phenotype which we theorize would be more effective in in vivo models of ischemic repair.   
Methods  
Maintenance of undifferentiated pluripotent stem cells 
Undifferentiated ES and iPS cells for use in stromal co-culture differentiation were grown 
in 6-well plates that were coated with a monolayer of irradiated mouse embryonic fibroblasts 
(MEF) at a density of 180,000 per well (high density).  Each plate was stored in incubators at 
37°C and 5.0% CO2, hereby referred to as standard conditions.  ES and iPS cells were passed on 
to fresh MEF plates every 6-7 days depending on confluency and amount of colonies that showed 
signs of differentiation (non-linear borders, 3-dimensional growth, discoloration).  If it was 
estimated that more than 10% of the colonies were undergoing differentiation, glass picking 
sticks would be used to remove the unwanted colonies.  Wells were fed daily with 2.5mL of ES 
media containing 15% knockout serum replacement, 1% non-essential amino acids (NEAA), 1% 
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L-glutamine, 0.5% pen/strep, 1x β-mercaptoethanol, and 8ng/mL bFGF.  Removal of 
undifferentiated cells was done by incubating each well in 1mL of 1mg/mL collagenase IV in 
DMEM-F12 media for 5 minutes.  Cells were mechanically scraped off with a glass pipette re-
suspended in ES media, and centrifuged for 5 minutes at 1500 RPM.  For undifferentiated cells, 
the supernatant was aspirated and the cells were re-suspended in ES media at concentrations of 
1:3 to 1:10 (based on well to number of milliliters of ES media used to re-suspend) and then 
added to 6 well plates containing new MEFs.   
Stromal cell co-culture differentiation 
M210 cells were grown to confluency on 150cm
2
 flasks and fed approximately every 
other day with M210 media containing 10% fetal bovine serum (FBS) and 1% pen/strep in RPMI.  
Expansion and passage of M210s was performed by removing the media from the flasks, washing 
with DPBS, and incubating in 0.05% trypsin-EDTA for 2-4 minutes.  The trypsin was quenched 
with FBS-containing media as cells were collected and centrifuged at 1500 RPM for 5 minutes.  
The supernatant was aspirated and the cells were resuspended at the desired concentration in fresh 
M210 media.  Upon reaching confluency, the M210 media was collected and temporarily stored 
in a 50mL conical tube.  Mitomycin C was added to this media for a final concentration of 
10ng/mL and returned to the M210 flask.  The M210 cells were incubated for 3 hours at standard 
conditions in the mitomycin C-treated media, after which the media was collected and stored 
according to proper waste disposal guidelines.  The cells were washed three times with DPBS 
which was also stored with the mitomycin C media when collected.  M210 cells were then 
incubated with 0.05% trypsin-EDTA until they were non-adherent and collected in FBS-
containing media to quench the trpysin.  Each well of a 6 well plate was seeded with 160,000 
M210 cells and allowed to adhere overnight. 
ES/iPS cells were harvested according to the methods previously described for passaging 
cells and were added to the confluent M210 6 well plates at a ratio of 1:6-1:10.  The cells for 
differentiation were fed with R15 media containing 16% characterized FBS, 1% NEAA, 1% L-
glutamine, 1% pen/strep, and 1x β-mercaptoethanol in RPMI.  The media was changed every 
other day for 12-14 days at which point the cells were collected and sorted by MACS.  CD34+ 
and CD31PE+ kits (Stemcell Technologies, Vancouver) and CD31+ kits (Miltenyi Biotech, 
Auburn CA) were used according to the manufacturer’s protocols.   
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Primary endothelial cell culture 
 Human umbilical arterial endothelial cells (HUAEC) and Human lymphatic endothelial 
cells (HLEC) were obtained from ScienCell, Human umbilical venous endothelial cells (HUVEC) 
were obtained from LifeLine.  Cells were thawed and plated on to 25cm
2
 flasks that were pre-
coated with 10ng/mL fibronectin.  Each flask was fed with EGM-2MV media (Lonza) every 
other day and cells were passed when roughly 80% confluency was achieved.  When cells 
reached passage 10 or greater they were not used for any experiments and were discarded. 
Spin EB differentiation 
 ES and iPS cell lines were adapted through routine passage with TrypLE (Life 
Technologies, Carlsbad) on low density (90,000/10cm
2
 well) MEFs.  At roughly 12-15 passages 
of adaptation, cells were harvested and re-suspended in standard spin EB media containing 10% 
de-ionized bovine serum albumin, 5% polyvinyl alcohol, 1x synthechol solution, 1x linoleic acid, 
1x linolineic acid, 5mg/mL ascorbic acid 2-phosphate, α-Monothioglycerol (13µL in 200mL of 
media), 1mM glutamax I, 1x pen/strep, 5% (v/v) protein-free hybridoma mix, and 1x insulin-
transferrin-selenium.  96-well plates were prepared by adding sterile water to the outer wells prior 
to adding the cells in spin EB media to the rest of the wells at a concentration of 3,000 
cells/100µL of media in each well.  The plates were then centrifuged at 1400 RPM to collect the 
cells at the bottom of the wells and form embryonic bodies.  Following one day of incubation, 
70µL of spin EB media was removed from each well and replaced with an equal volume of 
differentiation media #1 containing 2% serum replacement media 3 (Sigma-Aldrich, St. Louis), 
1% L-glutamine, 1% NEAA, 0.004% α-Monothioglycerol, and 50ng/mL each of VEGF (R&D 
Systems, Minneapolis), bFGF (Peprotech, Rocky Hill NJ), and BMP-4 (Peprotech) in IMDM 
basal media.  At day 6 of differentiation, 70µL of differentiation media #1 were removed and 
replaced with 70µL of differentiation media #2 which is the same as #1 except it contains no 
BMP-4.  On Day 7, the Spin EBs were harvested and magnetically sorted. 
Magnetic Sorting (Miltenyi Kit) 
Prior to sorting, cells were dissociated with trypsin and were filtered with 70µM filters to reduce 
clumping.  In the case of spin EBs, the EBs were collected with a multichannel pipette and were 
incubated with trypsin in a 15mL conical.  Following neutralization of the trypsin with FBS-
containing media, cells are resuspended in Easy Sep media containing 2% FBS and 0.2% EDTA 
(1mM) in dPBS.  After removing a small amount of cells to be used in pre-sort flow cytometry 
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analysis, the whole cell population is resuspended at a maximum concentration of 1x10
7
 cells per 
60µL of Easy Sep media.  20µL of FcR blocking reagent is added per 1x10
7
 cells and mixed 
briefly before adding 20µL of CD31 microbead mixture which consisted of anti-CD31 antibodies 
conjugated to magnetic beads.  This mixture is incubated at 4°C for 15 minutes.  Cells are then 
washed with at least 1mL of Easy Sep media to remove unconjugated antibodies.  MACS 
separation LS columns (Miltenyi) were prepared by inserting them into the mini MACS magnet 
and by allowing 1mL of Easy Sep media to completely run through the column.  Following this, 
the cells (resuspended in 500µL of Easy Sep media) are added to the column and allowed to run 
through.  When the media has all flowed through, 500µL of media is added and allowed to flow 
through three times.  After the third time, the column is removed from the magnet and placed in a 
fresh 5mL round bottom tube.  1mL of media is added and the plunger provided is used to rapidly 
flush the cells from the column into the round bottom tube.  Cells are counted and some are 
allocated for post-sort flow cytometry analysis while the majority are resuspended in EGM-2MV 
(supplemented with 50ng/mL of VEGF) and plated on dishes coated with fibronectin. 
Magnetic Sorting (EasySep kit) 
Cells are collected the same way as described in the Miltenyi method above.  Total cell 
populations totaling less than 5 x 10
7
 were re-suspended in 250µL of Easy Sep media, 
populations totaling between 5 x 10
7
 – 2 x 108 were re-suspended at a concentration of 2 x 108 
cells/mL.  The EasySep Positive Selection Cocktail was added at a concentration of 100µL/mL of 
cells and incubated at room temperature for 15 minutes.  Following this, EasySep Magnetic 
Nanoparticles were added at a concentration of 50µL/mL and incubated at room temperature for 
10 minutes.  2.5mL of Easy Sep media was added after this time and the mixture was gently 
pipetted up and down to dissociate any clumps.  If large aggregates remained, the cells would be 
passed through 100µm mesh filters.  The tube containing cells for selection was then placed 
inside of the EasySep magnet for 5 minutes.  After this time the tube was inverted while still in 
the magnet in order to pour off the supernatant fraction.  The tube was then removed from the 
magnet and a fresh 2.5mL of EasySep media was added and the tube was replaced in the magnet.  
This process was repeated for a total of three times altogether.  Following the final inversion, the 
tube was removed from the magnet and the cells remaining were resuspended in endothelial 
growth media and plated on fibronectin-coated flasks or set aside for flow cytometry analysis.    
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Immunocytochemistry 
Cells to be analyzed were harvested and re-plated on 8-chambered slides (Nunc, Rochester NY) 
that had been pre-coated with fibronectin (10ng/mL).  After about a day of growth, each chamber 
was washed with dPBS and 10% formalin was used to fix the cells for 15 minutes at room 
temperature.  The chambers were washed with dPBS again and the cells were permeabilized with 
0.2% (v/v) Triton-X in dPBS for no more than 5 minutes.  A third wash with dPBS was 
performed and the cells were then incubated with blocking serum (10% (v/v) FBS and 2% (w/v) 
BSA in dPBS) for one hour at room temperature.  Primary antibodies were diluted to roughly 1-
2ng/mL in blocking serum and added to each chamber to incubate overnight at 4°C.  Following 
another wash with dPBS the next day, secondary antibodies diluted to the same concentration in 
dPBS containing 10% of the serum of the host animal the antibody was obtained from were added 
to the chambers.  These antibodies incubated on the cells for one hour at room temperature and 
were washed with dPBS following incubation.  Chamber dividers were removed and ProLong 
Gold with DAPI (Life Technologies) was added prior to visualization.  Antibodies used are 
mouse anti-human CD31 (eBioscience, San Diego), mouse anti-human CD34 (BD Biosciences, 
San Jose), mouse anti-human Von Willebrand Factor (Dako, Carpinteria), mouse anti-human 
eNOS/NOS type III (BD Biosciences), mouse anti-human CD144 (eBiosciences), mouse IgG1 
iso control (eBiosciences), rabbit anti-human α-smooth muscle actin (abcam, Cambridge, UK), 
mouse anti-human SM22 (abcam), mouse anti-human calponin (Sigma Aldrich, St. Louis), 
donkey anti-mouse Cy3-conjugated IgG (Jackson ImmunoResearch Laboratories, West Grove), 
donkey anti-rabbit FITC-conjugated IgG (Jackson ImmunoResearch Laboratories), donkey anti-
rabbit Cy3-conjugated IgG (Jackson ImmunoResearch Laboratories), goat anti-mouse alexafluor 
488 IgG (Life Sciences), donkey anti-rabbit alexafluor 555 (Life Sciences).  
Flow Cytometry 
Cells prepared for flow Cytometry were filtered and resuspended in FACS buffer (2% (v/v) FBS 
and 1% (v/v) of 10% sodium azide in dPBS) at roughly 10,000 to 50,000 cells per sample.  Prior 
to analysis, cells were incubated with fluorophore-conjugated primary antibodies specific for cell 
surface antigens at 4°C for 20 minutes.  Following incubation, cells were washed with FACS 
buffer and the supernatant was aspirated following centrifugation at 1500 RPM for 3-5 minutes to 
remove any excess unbound antibody.  Immediately prior to analysis, 7-aminoactinomycin 
(7AAD, Sigma Aldrich) was added to a final concentration of 2ng/mL.   Cells were analyzed with 
either a FACScalibur or LSR II (BD Biosciences) flow cytometer system.  Collected data was 
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analyzed using Flowjo software (TreeStar, Ashland). All antibodies used for flow cytometry 
applications are mouse anti-human from BD Pharmingen (San Jose) unless otherwise noted.  
APC-conjugated antibodies used are CD31 mouse anti-human (Thermo Scientific, Waltham MA) 
and CD73 mouse anti-human  (eBioscience).  PE-conjugated antibodies used are CD102 mouse 
anti-human (Biolegend, San Diego), CD144 mouse anti-human (eBiosciences), APLNR rabbit 
anti-human (Bioss, Boston), VEGFR3 mouse anti-human (Biolegend), Neuropilin-2 rabbit anti-
human (Bioss), Neuropilin-1 mouse anti-human (R&D Systems), Streptavidin (BD Biosciences).  
Biotin-conjugated antibody used was CXCR4 mouse anti-human (eBioscience).  
PI3K-inhibitor Assays 
Cells were plated at a concentration of 1.0 x 10
5
/well on Nunc 6-well plates and allowed to 
recover for 24 hours or until confluency was reached.  24 hours prior to analysis, LY294002 
(Cayman Chemical, Ann Arbor), PI-103 (gifted from Dr. David Largespada’s lab) and/or 8-Br-
cAMP (Enzo Life Sciences, Farmingdale NY) were added to EGM-2MV media at pre-
determined volumes which resulted in the desired experimental concentrations.  Cells were 
incubated with or without PI3K inhibitor/cAMP for 24 hours.  After this time, cells were 
collected with trypsin if used for qrt-PCR analysis or non-enzymatic dissociation solution (Sigma 
Aldrich) if used for flow cytometry as trypsin can cleave the CXCR4 protein.  Cells used for flow 
cytometry were prepared as described earlier and first incubated with a biotin-conjugated CXCR4 
mouse anti-human antibody (eBioscience) diluted 1:50 in Easy Sep buffer.  Following incubation 
on ice for 20 minutes, the cells were washed twice in Easy Sep buffer.  PE-conjugated 
streptavidin beads (BD Biosciences) were then added to the cells at a concentration of 1:100 in 
Easy Sep buffer and incubated on ice for 15 minutes.  These cells were then washed twice in Easy 
Sep buffer and prepared and analyzed under standard flow cytometry protocol. 
Quantitative Real-Time Polymerase Chain Reaction (qrt-PCR) 
Cells to be analyzed were collected and resuspended in buffer RLT and added to Qiashredder 
tubes (Qiagen, Germantown MD).  Use of these tubes followed the manufacturer’s instructions.  
Following this, the flow through was added to RNeasy Mini Kit (Qiagen) tubes and 
manufacturer’s instructions were followed.  RNA was analyzed using the NanoDrop 1000 
Spectrophotometer (Thermo Scientific) for concentration and purity.  RNA not immediately 
being converted to cDNA was stored at -80°C.  The Superscript III First Strand system (Life 
Technologies) was used to generate cDNA from the RNA collected during which the 
manufacturer’s instructions were followed.  Analysis of gene expression was done with SYBR 
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Green (Life Technologies) in 96-well Thermo-Fast Detection Plates (Thermo Scientific) using the 
Mastercycler Realplex
2
 thermocylcer (Eppendorf) and the associated software.  Primers used for 
this analysis were:  
GAPDH forward  CCACTCCTCCACCTTTGAC FOXC1 forward GGCGAGCAGAGCTACTAC  
GAPDH reverse ACCCTGTTGCTGTAGCCA  FOXC1 reverse TGCGAGTACACGCTCATGG 
HES1 forward CAGGACACCGGATAAACCAAA RBPJ forward AACAAATGGAACGCGATGGTT 
HES1 reverse CTTTCATTTATTCTTGCTCTTCGTCTT RBPJ reverse GGCTGTGCAATAGTTCTTTCCTT 
CXCR4 forward ACCACAGTCATCCTCATCCTG NOTCH1 forward GAGGCGTGGCAGACTATGC 
CXCR4 reverse CACACCCTTGCTTGATGATTT NOTCH1 reverse CTTGTACTCCGTCAGCGTGA 
COUPTFII forward ATAGTCCTGTTCACCTCAGATGC NOTCH4 forward TGTGAACGTGATGTCAACGAG 
COUPTFII reverse CCTACCAAACGGACGAAAAA NOTCH4 reverse ACAGTCTGGGCCTATGAAACC 
PROX1 forward GGGAAGTGCAATGCAGGA  JAG1 forward GTCCATGCAGAACGTGAACG 
PROX1 reverse GTACTGGTGACCCCATCGTT JAG1 reverse GCGGGACTGATACTCCTTGA 
EPHB2 forward AGAAACGCTAATGGACTCCACT JAG2 forward TGGGACTGGGACAACGATAC 
EPHB2 reverse GTGCGGATCGTGTTCATGTT JAG2 reverse AGTGGCGCTGTAGTAGTTCTC 
EPHB4 forward CGCACCTACGAAGTGTGTGA DLL4 forward GCCCTTCAATTTCACCTGGC 
EPHB4 reverse GTCCGCATCGCTCTCATAGTA DLL4 reverse CAATAACCAGTTCTGACCCACAG 
 
Matrigel Tube-Forming Assay 
Prior to cells being harvested, 24-well Nunc plates were coated with recently thawed growth 
factor-reduced matrigel (BD Biosciences) supplemented with VEGF (R&D Systems) to a 
concentration of 50ng/mL.  The matrigel was spread with a P1000 pipette tip while avoiding 
creation of bubbles.  After evenly spreading the matrigel along the bottom of each well 
(~100µL/well), the plate was incubated for at least 30 minutes at 37°C.  After this time, harvested 
cells resuspended in EGM-2MV were added to each well at a concentration of 50,000-100,000 
per well.  Analysis of tube formation was done 18-24 hours later except where indicated.   
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Results 
Stromal Cell Co-Culture Differentiation 
In order to generate endothelial and smooth muscle cells, H9 embryonic stem cells as well as 
induced pluripotent stem cells generated from neonatal human dermal fibroblasts (miPS16 line) 
and umbilical cord blood cells (UCBiPS7 line) were cultured according to established pluripotent 
stem cell protocols.  Both iPS lines were generated in the Kaufman lab and all lines were 
previously characterized for expression of stem cell markers as well as ability to form teratomas 
in vivo.  All lines were used for experiments that showed their ability to differentiate into various 
cells of the hematopoietic lineage such as natural killer cells and mesenchymal stem cells.  The 
initial differentiation strategy involved co-culture of undifferentiated cells with inactivated M210 
mouse bone marrow stromal cells in media containing 20% FBS.  While the media did not 
necessarily direct differentiation specifically towards an endothelial lineage, M210s have been 
shown to increase the development of hematopoietic cells through cell to cell interactions that 
replicate the hematopoietic niche to a degree.  Because of this approach, pluripotent colonies 
expanded rapidly and differentiated quickly with cells at the center of colonies forming 3-
dimensional structures while cells at the edges tended to remain as a monolayer.  For this reason 
it was important to limit the number of cells that were initially plated as too dense of a starting 
population would result in poor differentiation of endothelial cells.   
 On day 12-14 of differentiation, cells were harvested and sorted magnetically initially for 
positive selection of CD34+ cells and later for CD34+/CD31+ cells.  The pre-sort populations 
typically consisted of about 2-8% double positive cells for these markers (Fig. 1A) so in order to 
get a usable post-sort population large quantities of cells were needed.  Given the prolific nature 
of the differentiating cells this was not an issue as anywhere from 3.0x10
7
 to 1.0x10
8
 total cells 
could be collected for sorting.  However, limitations of the Easy Sep sorting system made use of 
anything less than 7.0x10
7
 ideal due to clogging of the sorting column and inefficient magnetic 
binding.  Analysis of the pre-sort population showed that the majority of cells (~90%) were 
negative for any endothelial markers with the exception of small populations that were 
CD73+/CD34- and CD146+/CD34-.  CD73 and CD146 are not unique to endothelial cells, as 
they are expressed on a variety of hematopoietic cells with the former present on regulatory T 
cells
70
 and mesenchymal stem cells
71
 while CD146 is found on a subset of activated 
lymphocytes
72
 as well as MSCs and fibroblasts
73
.  Despite this shared expression among unique  
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Figure 1. Stromal cell co-culture differentiation of endothelial cells. (A) Flow 
cytometry data from a CD34
+
 MACS sort following 12 days of differentiation in 
stromal cell co-culture. (B) Flow cytometry analysis following two passages post-sort  
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cell types, mature endothelial cells possess a CD31+/CD73+/CD146+ phenotype so it was 
determined that the small populations seen with this phenotype were committed to that lineage.  
Flk1 is the primary receptor for vascular endothelial growth factor on endothelial cells, making it 
a useful marker for EC identification.  While only a small percentage of the cells showed 
CD31+/Flk1+ expression (Fig. 1A) this may be attributed to a weak antibody as later experiments 
showed more robust expression during analysis but does not entirely rule out lower levels of Flk1 
present using this differentiation method.  As noted earlier, efficiency of the Easy Sep magnetic 
sorting system decreased if the starting population was too numerous.  Roughly 9.0x10
7
 cells 
were used in the sort shown in figure 1 but only about 0.6% were recovered after the sort.  This 
inefficiency can also be seen in that roughly 20% of the post-sort cells are negative for the 
endothelial markers being analyzed.  This problem became more evident as the sorted population 
was allowed to expand in standard endothelial conditions resulting in complete loss of endothelial 
phenotype after only a few passages (Fig. 1B). 
Spin EB Differentiation 
 The inefficiency of the differentiation using the stromal co-culture method, compounded 
with the overgrowth of sorted cultures by fibroblast-like cells, forced us to reconsider our 
methods and try to develop a new protocol for endothelial differentiation.  Our lab had shown 
success in generating NK cells using a feeder free method that was adapted from a previously 
published protocol utilizing a defined differentiation media to support spin embryoid bodies (spin 
EB)
12,74
.  This system not only increased the efficiency of hematopoietic differentiation, but it was 
also beneficial in reducing the time needed for differentiation as well as eliminating the need for 
co-culture with murine fibroblasts.  Another essential benefit to this method is the use of only 
recombinant proteins in the media which eliminates the need for animal products to be used in the 
culture.  Also, by using a defined number of cells in the culture, the problems that arose from 
differentiation cultures being too dense and thus affecting the capacity to induce endothelial 
differentiation were eliminated.  For these reasons, this system was utilized in an effort to 
standardize and improve endothelial differentiation efficiency as well as purity of sorted 
populations.    
 While this spin EB system was designed with hematopoietic differentiation in mind, it's 
efficacy of generating viable endothelial populations was not initially realized using the standard 
protocol.  The typical hematopoietic differentiation in the BPEL (bovine serum albumin 
polyvinyl alcohol essential lipids) media utilized the cytokines VEGF, SCF, and BMP-4 and was 
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allowed to proceed for twelve days .  Analysis of day 5 differentiation showed much more robust 
expression of CD31+/CD73+/CD34+ populations than were ever seen in stromal cell co-culture 
differentiations (FIG2 A).  By day 7 we could see roughly 56% CD31+ expression in the whole 
cell population along with about 39.4% CD31+/CD34+, 10.9% CD31+/CD73+, and 14.5% 
CD31+/CD146+.  By using the spinEB system we had greatly improved our ability to generate 
cells expressing endothelial markers in half the time it took to differentiate cells using the stromal 
co-culture method.  At this point we also tried a new magnetic sorting method using Miltenyi 
columns and CD31 magnetic antibodies instead of CD34 antibodies used in co-culture sorts.  
Considering that nearly all CD34+ cells collected from those previous sorts were also 31+, this 
alternate method increased post-sort yields by reducing stress on the cells from being out of 
normal conditions as well as seemingly performing better at retaining cells bound by the magnetic 
antibodies during the process (Fig. 2B).   
 Inspired by these results, we sought ways to further refine the process and increase yields 
of endothelial cells that would remain viable for multiple passages post-sort.  We noticed that 
ECs collected from SpinEBs using the standard BPEL differentiation media would only expand 
for a few passages before a reduction in endothelial markers was observed followed by 
senescence.  Since this media is meant for definitive hematopoietic differentiation, we needed to 
adjust it to drive differentiation towards the hematoendothelial lineage.  At this time we were also 
running experiments using a defined media containing VEGF, BMP-4, and basic fibroblast 
growth factor (bFGF), hereafter referred to as VBF, as opposed to the VEGF, BMP-4, SCF 
(VBS) cytokine composition of the standard media.  This VBF media did not contain the same 
non-cytokine components essential for formation of EBs as VBS.  As a result, using it in place of 
the latter resulted in negligible embryoid bodies which were unsustainable for differentiation.  To 
address this, we tried using VBF cytokines in the standard BPEL media.  By replacing SCF with 
bFGF, we observed roughly similar levels of CD31, CD34, and CD73 expression but a noticeable 
increase in CD146 expression (Fig. 2C). We also began analyzing cells at this point for 
expression of CD102, also known as intercellular adhesion molecule 2 (ICAM2), which was 
found to be reliably expressed at high levels on mature endothelial cells.  Modifying the cytokines 
used also showed little effect on increasing long term viability of the sorted population as the 
early senescence seen using the VBS media was also evident in the VBF media differentiation. In 
order to obtain the benefits to differentiation of the spin EB system and increase the viability of 
the sorted ECs, we next tried setting up the cells for differentiation initially in the standard  VBS 
media followed by switching to the VBF media after one day. 
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Figure 2.  Spin EB differentiation of endothelial cells from hESCs (A) Phenotype of 
cells at D5 of differentiation using BPEL media. (B) Expression of extracellular markers 
analyzed by flow cytometry following MACS sorting for CD31
+
 cells. (C) Pre-sort data 
for cells in VBF differentiation media instead of BPEL media. (D) Pre-sort data for cells 
differentiated for one day in VBS media and switched to VBF at D1. 
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It was theorized that allowing the embryoid bodies to develop in the VBS media, which contains 
the necessary components for EB formation, we could then switch to the VBF media in order to 
drive differentiation towards a more committed EC lineage.    Initially, we found that switching 
the media at D1 did not increase marker expression to the levels we had anticipated (Fig. 2D).  
Comparing the expression profile of cells differentiated with either BPEL + VBS or BPEL + VBS 
switched to VBF (VBS-VBF) at day 1, we see that there tends to be higher expression of these 
double positive cells in BPEL + VBS versus the latter method (Table 1).  While the increase of 
EC markers makes it seem that BPEL + VBS is the better of the two, it should be noted that the 
early hematopoietic marker CD43 is vastly increased in comparison to VBS-VBF as well as 
rising CD45, a more definitive hematopoietic marker, at later dates.  This increase of 
CD31+/CD43+ and CD31+/CD45+ cells may contribute to the deficiencies of long term viability 
of cells sorted for CD31.  We did find that cells differentiated in VBS-VBF were able to maintain 
an endothelial phenotype for more passages as well as avoid senescence so we adopted this 
method for our future differentiation experiments.  Following removal of the EBs for sorting, it 
was noticed that cells with an endothelial morphology that had been expanding outward from the 
EB (Fig. 3A) were left in the well.  These cells were fed with standard endothelial growthmedia 
(EGM-2MV) and allowed to expand.  After a week, these cells showed strong expression of 
endothelial markers albeit with a small portion of CD31-/CD73+/CD90+/CD102-/CD105+ cells 
which is indicative of a mesenchymal-like population(Fig. 3B).  Considering that our mature 
endothelial cells were grown on fibronectin, we investigated whether differentiating EBs on 
fibronectin-coated wells would increase the growth of these ECs that emanated from the 
embryoid body.  We found that this actually greatly diminished the capacity for endothelial 
differentiation (Fig. 3C) and interestingly reduced the expression of αVβ3 integrin, a receptor 
known to bind fibronectin and promote binding and cellular expansion
75
.  Since addition of 
fibronectin showed a negative effect on EC differentiation, we examined whether we could 
further increase EC differentiation as well as increase long term viability in our spin EB system 
by modifying the temporal exposure to specific cytokines.  While the three cytokines of VBF 
differentiation media are all required for mesoderm commitment as well as subsequent 
hematoendothelial commitment, BMP-4 has been shown to be unnecessary beyond this second 
stage as it does not contribute to further development along these lineages
76
. Considering the 
success of VBF media in generating cells that were phenotypically hemagioblasts, a precursor 
capable of both endothelial and hematopoietic lineage commitment, we examined whether 
removal of BMP-4 prior to sorting at day 7 would increase endothelial commitment at the 
expense of hematopoietic commitment. By switching the VBF media to media without BMP-4  
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Figure 3 
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Figure 3. Endothelial cells expand outward from EBs but do not differentiate well on fibronectin. (A) Spin EB at 
D7 of differentiation in VBS-VBF media.  The EB is at the center with an outgrowth of EC-like cells surrounding it 
(left).  Adherent cells that remained after mechanical removal of the EB for sorting following one week of being 
fed with EGM-2MV (right). (B) Flow cytometry analysis of the adherent cells shown above. (C) Flow cytometry 
analysis at D7 of Spin EB differentiation both without (top) and with (bottom) fibronectin coating on the wells. 
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CD31 
only 
CD34 CD43 CD45 CD73 CD90 CD102 CD105 CD140b CD146 
D7 - BPEL + VBF cytokines 49 38.9 0 0 12.8 44.8 45.2 17 3.91 28 
D9 - BPEL + VBF cytokines 62 31.3 40 1.38 8.82 33.6 55 23.5 5.9 27.2 
D13 - BPEL + VBF cytokines 54 28.5 37.9 6.54 8.71 21.5 51.7 33.7 13.8 14.9 
D7 - VBS-VBF media 28.5 23.9 0 0 11.9 28.2 26.6 17 10.6 21.2 
D9 - VBS-VBF media 47 25.3 10.9 0.79 14.6 48.9 34.4 7.68 11.2 24.8 
D13 - VBS-VBF media 19 14.4 6.42 1.81 10.6 15 18.3 11 3.96 8.83 
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Spin EB Defined Media Differentiation 
Table 1. Comparison of endothelial and hematopoietic marker expression between BPEL 
+ VBF and VBS-VBF media. Analysis based on flow cytometry of hematopoietic and 
endothelial surface markers following differentiation in BPEL + VBF cytokines or VBS-VBF 
differentiation media.  Cells were analyzed at days 7, 9, and 13.  Each set of data except "CD31 
only" represents the percentage of cells double positive for CD31 and the specific marker 
indicated. 
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(VF) at day 6, we saw an even further increase in endothelial marker expression the following 
day with roughly 72% of the pre-sort cells being CD31+ (Fig. 4A).  We also saw large increases 
in double positive populations for CD31 and other markers except for a minimal increase in 
CD31+/CD73+ cells.  Also promising was the efficiency of the CD31+ sorting as less than 0.1% 
of the post-sort analyzed cells were CD31-.  After a week in endothelial growth media, we saw 
that there was still nearly 100% CD31+ cells and that the double positive populations had 
increased with the exception of CD31+/CD146+.  The CD31+/CD73+ fraction had greatly 
increased from 12.4% to 82.8% over the course of 7 days.  These cells were analyzed and passed 
each week when they reached confluency and continued to show robust EC marker expression for 
more than 6 weeks as well as no evidence of expansion of the minimal CD31- population that 
was present (Fig. 4B).  We noticed that CD90 (also known as thy1), which is only present on 
activated endothelial cells
77
, was present at high levels at early time points and slowly diminished 
to near undetectable levels at later analyses.  The reasons for this are unknown at this point but 
may be evidence for inflammatory cytokine release in the post-sort cell population.  
Characterization of differentiated endothelial cells 
 In order to further characterize the endothelial cells that we were able to isolate and 
maintain in long term culture, we used immunocytochemistry (ICC) to evaluate the expression of 
both extracellular and intracellular proteins (Fig. 4C).  While the expression of CD31 and CD144 
that was shown in flow cytometry analysis was confirmed, we also saw expression of the 
endothelial-specific intracellular proteins Von Willebrand factor (VWF) and endothelial nitric 
oxide synthase (eNOS).  Von Willebrand factor is a critical component of the clotting process 
following injury to vascularized tissue and eNOS, as its name implies, generates nitric oxide 
which is required for vasodialation and reduce constriction of vessels.  The presence of both of 
these components is strong evidence for the development of mature endothelial cells in our 
culture based on comparison to HUVEC protein expression.  In order to analyze the functional 
capacity of these cells we performed a tube forming assay by plating the cells on matrigel-coated 
plates.  Mature endothelial cells grown on matrigel will form rudimentary two-dimensional tube-
like structures within a few hours, a process that resembles in vivo vessel formation.  We 
observed that the ESC-derived ECs showed similar tube structures compared to HUVECs with 
multiple branch points from the "hubs" and extensive networks being formed (Fig. 4D).  Based 
on the endothelial protein expression and functional similarity to primary cells in our ESC-
derived ECs, we determined that our differentiation protocol is able to generate mature 
endothelial cells reliably and effectively. 
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Figure 4 
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Figure 4.  hESC-derived ECs express 
endothelial markers and are functionally 
similar. (A) Surface marker expression of 
differentiating EBs at D7 after switching from 
VBS-VBF to media without BMP-4 at D6. (B) 
Long term analysis of CD31
+
 cells in standard 
endothelial culture.  The cells were passage 6 at 
the D40 time point. 
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Figure 4. (C) 
Immunocytochemistry images 
of ES-derived ECs for typical 
EC markers show positive 
expression of both intracellular 
and extracellular proteins 
CD31, CD144, VWF, and 
eNOS. (D) Matrigel tube 
formation assays with 
HUVECs (top) and H9 ECs 
(bottom).  Images were taken 
after 18 hours of culture. 
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Smooth muscle cell differentiation from sorted endothelial cells
 
 While endothelial cells are the primary component of blood vessels, they are also 
complemented by perivascular smooth muscle cells and pericytes which provide stability and 
modulate vessel dialation.  Previous studies, as well as experiments in our lab, have shown that 
vascular progenitors are capable of differentiating into smooth muscle cells in the presence of the 
cytokines PDGF-BB and TGF-β78,79.  By switching the endothelial growth media to media 
containing these cytokines relatively shortly after sorting, a small portion of these cells would 
further differentiate into SMCs.   The efficiency of this process was seemingly dependent on how 
many of the sorted cells were committed to the endothelial lineage as the majority of cells became 
non-adherent following introduction of the SMC differentiation media.  Cells that remained 
adherent assumed a SMC morphology including an increase in size, loss of cell to cell contact, 
and development of intracellular filaments (Fig. 5A).  We used ICC to examine the expression of 
SMC specific proteins smooth muscle actin, SM22-α, and calponin (Fig. 5B).  We also saw that 
these cells lost the ability to form tubes on matrigel and instead formed large clumps instead of 
tubes (Fig. 5C).  However, by co-culturing ECs with SMCs on matrigel we saw that not only was 
the ability to form tubes recovered, but also that the tubes were thicker and more robust which 
mimic the ability of these cells to create thicker vessels in vivo.  By using ECs derived from a 
GFP-expressing ESC line as well as SMCs from a mCherry-expressing ESC line, we could see 
that both cell types were evenly distributed throughout these tubes and contributed equally to 
their formation (Fig. 5D).  This process began within an hour after introduction of the cells to the 
matrigel and tube formation was mostly complete by 3 hours (Fig. 5E).  Combined with our 
characterization by flow cytometry and ICC, this assay showed we had derived functional ECs 
and SMCs from ES cells.  
Apelin enhances endothelial differentiation 
 In an additional effort to further optimize our differentiation protocol for developing 
vascular progenitors and subsequent EC and SMC generation, we looked at the use of known 
enhancers of vascular development.    We analyzed the effect of introducing APLN to our VBF 
media at days 1 and 3 of EB differentiation in both ES and iPS cells.  We saw that at day 4 there 
was little difference in CD31+ populations as well as double positive CD31+/CD34+, 
CD31+/CD73+, and CD31+/CD102+ populations (Fig. 6A).  By day 6 however, we saw that 
APLN added at D3 caused a noticeable increase in the total CD31+ cells (Fig. 6B).  Additionally, 
the CD31+/CD102+ population showed a similar increase while the CD31+/CD34+ increase was  
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Figure 5. Smooth muscle cells from 
hESCs express SMC-specific markers 
and can form tubes with ECs in vitro. 
(A) Phase image of cells with a smooth 
muscle cell phenotype following 
differentiation from CD31
+
 sorted cells. 
(B) Immunocytochemistry images for 
H9-derived SMCs showing α-SMA, 
calponin, and SM22 expression. 
29 
 
 
C                                                                           D 
 
E 
1 Hour                                                                    2 Hours 
 
3 Hours 
 
 
 
Figure 5. (C) Image taken following 18 
hours of ESC-derived SMCs in a 
matrigel tube formation assay. (D) Co-
culture of GFP-ECs and mCherry-
SMCs show equal contribution to the 
tubes that form. (E) Time lapse assay 
of GFP-ECs and mCherry-SMCs.  
Migration of the green ECs can be seen 
to contribute to the tube formation 
which is robust by 3 hours in culture.  
Images are not from the same area at 
each time point.  
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less pronounced and CD31+/CD73+ populations were diminished when APLN was added at both 
days 1 and 3 compared to the control group.  By day 8 we saw much higher increases in CD31+ 
cells in both D1 and D3 APLN treatments as well as CD31+/CD102+ cells.  Consistent with D4 
and D6 analyses, the CD31+/CD34+ populations were similar among both APLN treatments and 
the control and CD31+/CD73+ development was diminished in the presence of APLN compared 
to the control (Fig. 6C).  Subjecting umbilical cord blood-derived iPS cells to the same treatment 
resulted in similar expression patterns overall but with slightly diminished percentages across the 
board which may be due to the reduced capability of those iPS cells to undergo hematovascular 
differentiation (Fig. 6D) These moderate increases in surface markers did not necessarily 
translate to improved endothelial long-term viability as sorted cells from these differentiation 
conditions did not retain an EC phenotype any better after multiple passages than without APLN 
added.   
DAPT enhances expression of endothelial markers 
 Another method of encouraging vascular development we investigated was to utilize 
DAPT, a small molecule inhibitor of notch signaling, in VBF media at various time points during 
differentiation.  Recent studies have shown that inhibition of notch signaling after commitment to 
the hemangioblast lineage can encourage endothelial differentiation at the expense of 
hematopoietic commitment
19
.  We expanded upon our treatment schedule compared to APLN by 
adding DAPT at days 1, 4, 7, and 12 in an effort to find the optimal time point at which the most 
cells would be considered committed to the hemangioblast lineage.  We found that the most 
significant increases in EC markers was found on day 7 of analysis when DAPT was added at day 
4 of differentiation (Fig. 6E).  Experiments involving this treatment are ongoing so we have not 
been able to characterize the ability of DAPT-treated EC differentiation for long term viability, 
but these early results are encouraging.  
Characterization of arterial, venous, and lymphatic endothelial cell phenotypes 
 Once we established a reliable protocol for development of phenotypically and 
functionally similar ECs from pluripotent cell sources, we next sought to compare these cells to 
primary arterial, venous, and lymphatic endothelial cells in order to determine whether our 
derived ECs possessed characteristics of any of these lineages.  When comparing the primary 
cells of these lineages, extracellular markers are not especially useful as all three EC types share 
similar expression patterns of most markers. However, we did find that some specific markers 
have slight variations between the three lineages (Fig. 7A).  Apelin receptor (APLNR), the 
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Figure 6. Apelin and DAPT 
promote higher expression of 
hemato-endothelial markers. (A) 
Day 4 phenotype analysis of cells 
differentiated in either VBF media 
alone, VBF+APLN at D1, or 
VBF+APLN at D3. (B) Day 6 
phenotype analysis of the same 
cells and (C) D8 analysis.  APLN 
greatly increased the expression of 
CD31 and CD102 while decreasing 
CD73. 
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Figure 6. (D) Expression patterns of differentiating UCBiPS7 cells at days 4, 6, and 8 (top).  
Each color represents either standard VBF media, VBF with APLN added at D1, or VBF with 
APLN added at D3 of differentiation.  Data represents percentage of total cells positive for 
the indicated markers analyzed with flow cytometry.  The bottom chart shows the same 
analysis done during differentiation of H9 ESCs. 
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Figure 6. (E) Expression patterns of cells double positive for CD31 and other endothelial markers in 
VBF differentiation with DAPT added.  The top categories on the x-axis describe media with DAPT 
added at days 1, 4, 7, 12, or with no DAPT added (un).  The bottom categories show the day of 
differentiation on which the cells were analyzed.  Each color represents the extracellular marker being 
analyzed fo co-expression with CD31. 
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receptor for the aforementioned apelin protein, was found to be expressed slightly higher on 
HUVECs than on HUAECs or HLECs.  Neuropilin-1 (NRP1) also had a slightly higher 
expression on venous cells than lymphatic or arterial cells, but expression was reasonably high 
for all three lineages.  We saw a more significant difference in the VEGF receptor 3 (VEGFR3) 
expression with both HUVECs and HUAECs less than that in HLECs.  While VEGFR2 is 
expressed at consistent levels across all three lineages, VEGFR3 is more specific to lymphatic 
ECs which was confirmed by our analysis
80
.  Considering the minimal differences in extracellular 
protein expression, we next used quantitative rt-PCR to examine the differences in gene 
expression profiles.  We identified upstream and downstream effectors of the notch signaling 
pathway (JAG1, JAG2, DLL4, HEY2 and HES1) as identifiers of an arterial endothelial 
phenotype.  Venous and lymphactic phenotypes were both identified with increased COUP-TFII 
expression while lymphatic ECs were further characterized by increased PROX1 expression.  We 
indeed found that JAG1, JAG2, and DLL4, ligands for notch receptors, were upregulated in 
primary arterial cells compared to both venous and lymphatic ECs (Fig. 7B).  NOTCH4 gene 
expression was also elevated in HUAECs compared to HUVECs and HLECs but NOTCH1 was 
found to be more highly expressed in HLECs.  Hes1 and Hey2, which are downstream products 
of notch-mediated transcriptional activation, were also found to be upregulated in arterial cells 
compared to the other two with Hey2 being significantly expressed (Fig. 7C).  COUP-TFII was 
found to be more highly expressed in both HUVECs and HLECs as we had expected and PROX1 
showed significant expression in HLECs compared to HUVECs and HUAECs.  Knowing that our 
primary cells showed the characteristic gene expression profiles of their lineage as well as that 
our primers were effective for qrt-PCR, we next compared H9-derived ECs to the three lineages.  
DLL4 was expressed more highly in all three primary cells compared to the H9 ECs while JAG1 
and JAG2 were upregulated compared to HUVECs and HLECs but not as much as HUAECs 
(Fig. 7D).  Interestingly, H9 ECs showed greater expression of COUP-TFII than all three primary 
cell lines but showed about equal PROX1 expression compared to HUAECs which is much lower 
than HLEC PROX1 expression.  
PI3K inhibition along with cAMP increases CXCR4 expression 
 In order to try and manipulate our pluripotent cell-derived ECs to adopt a more arterial 
phenotype, we examined using small molecule inhibitors and messengers of various signaling 
pathways in an effort to influence gene expression profiles.  Specifically, we analyzed the 
expression of CXCR4, which is more highly expressed on arterial ECs as compared to venous 
and lymphatic ECs, following inhibition of PI3K in conjunction with addition of cAMP. 
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Figure 7. Comparison of expression of lineage-specific genes between H9-ECs, HUAECs, 
HUVECs, and HLECs. (A) Flow cytometry analysis of expression of APLNR, Neuropilin-1, 
and Flt-4 in primary arterial, venous, and lymphatic endothelial cells.  Percentages are the 
number of cells bound by the PE-conjugated antibodies of each protein compared to IgG 
controls. (B) qrt-PCR analysis of gene expression in primary ECs.  Ratios are standardized to 
HUVECs for HUAECs and HLECs using the ΔΔCt method of analysis. 
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Figure 7. (C) qrt-PCR gene analysis of HUVEC, HLEC, and H9-ECs standardized to 
HUAEC gene expression.  The ratio of DLL4 and Hey2 expression in these three cell 
types compared to HUAECs is less than 0.1 for DLL4 and 0.0005 for Hey2.  (D) Similar 
analysis with HUAEC, HLEC, and H9-EC standardized to HUVECs.  The HUAEC ratio 
of Hey2 expression compared to HUVECs was over 8600 fold (not shown).   
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Treatment of HUAECs with LY294002, an inhibitor of PI3K, showed a large increase of CXCR4 
surface expression as measured by flow cytometry in a dose-dependent manner (Fig. 8A).  This 
increase was further amplified by the addition of 0.5mM cAMP both with and without 1μM or 
5μM LY294002.  Similar increases were seen in HUVECs treated under the same conditions, but 
with a lesser overall percentage of increase as compared to HUAECs considering the normal 
expression of the protein.  Measurement of Cxcr4 gene expression via qRT-PCR showed similar 
increases in both cell types while venous and lymphatic-specific genes, Coup-tfII and Prox1 
respectively, remained unchanged (Fig. 8B).  Applying these treatments to ESC-derived ECs 
resulted in similar increases of CXCR4 measured by flow cytometry (Fig. 8C).  Normal CXCR4 
expression in the untreated cells appeared to be less than HUAECs but more than HUVECs.  
Gene analysis also showed an increase in Cxcr4 with the fold change and pattern being similar to 
that which was seen in HUAECs (Fig. 8D).  These assays were performed for 24 hours, so we 
next looked at the expression of CXCR4 in ESC-derived ECs following treatment for 72 hours 
(Fig. 8E).  Treatment with 5μM LY294002 and 0.5mM cAMP for 24 hours followed by standard 
media for the next 48 hours showed a return to relatively normal protein levels by the end of the 
assay.  Addition of LY294002/cAMP every 24 hours showed an increase over the first 48 hours 
followed by a drop in the final day which may be a result of the toxicity of inhibiting PI3K 
activity for that period of time.  LY294002 has been shown to be slightly promiscuous in its 
binding targets and does not exclusively interact with members of the PI3K family
81
.  We tested 
the effects of PI-103, a more effective inhibitor of PI3K which also inhibits the mTOR signaling 
pathway
82
.  We saw tremendous increases in both extracellular protein expression as well as gene 
expression in ESC-derived ECs following treatment with the same concentration as LY294002 as 
well as cAMP (Fig. 8F).   
 While inhibition of PI3K along with cAMP increased CXCR4 gene and surface protein 
expression, we next wanted to analyze other arterial-specific genes to see if there was a similar 
effect.  The gene expression profiles of Notch1, Dll1, and Jag1 were analyzed given the 
importance of the notch signaling pathway in arterial cells.  Treatment of HUAECs with 
LY294002 showed increased transcription in all three genes at 1μM but only Notch1 at 5μM (Fig. 
9A).  Treatment with cAMP only showed the greatest increase in Notch1 across all conditions but 
increases similar to 1μM LY294002 treatment for Dll1 and Jag1.  Interestingly, the combination 
of both concentrations of LY294002 with cAMP showed decreases in expression of all three 
genes.  When HUVECs were subjected to these conditions, we found similar increases in Notch1 
transcription albeit not as drastically as HUAECs (Fig. 9B).  Also, treatment with 1μM  
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Figure 8. PI3K inhibitors 
and cAMP increase 
CXCR4 expression after 
24 hours. (A) Analysis of 
CXCR4 expression 
following treatment for 24 
hours with 0μM, 1μM, or 
5μM LY294002 as well as 
with the addition of 0.5mM 
8-Br-cAMP to each.  
Percentages are cells 
positive compared to 
streptavidin-PE only 
controls.  (B) qrt-PCR 
analysis of HUAECs and 
HUVECs following 
treatment LY294002 and/or 
8-Br-cAMP.  Each set of 
data represents three 
separate cell replicates.  
Fold change was calculated 
compared to untreated cells.   
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Figure 8. (C) Analysis of H9-ECs following 
treatment with LY294002 and/or 8-Br-cAMP 
for 24 hours as described in Fig. 8A.  (D) 
Gene expression analysis using qrt-PCR of 
H9-ECs.  (E) Longer term analysis of H9-EC 
CXCR4 expression treated with 5μM 
LY294002 at day 0, daily for three days, or 
untreated.  Cells were analyzed at daily for 
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Figure 8. (F) Flow cytometry (top) and qrt-PCR (bottom) analysis of 
H9-ECs treated with 0μM, 1μM, or 5μM PI-103 alone or with 0.5mM 8-
Br-cAMP.  Flow cytometry data shows comparison of CXCR4 
expression on treated cells compared to untreated controls.  Cells were 
analyzed 24 hours after treatment.   
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LY294002/cAMP did not produce the same reduction in transcription as seen with 
HUAECs.ESC-derived ECs showed a similar dose-dependent response to LY294002 in regards 
to Notch1 but slight decreases in transcription of Dll1 and Jag1 (Fig. 9C).  The combination of 
5μM LY294002 and 0.5mM cAMP also tended to decrease Notch1 expression compared to each 
individual treatment while 1μM LY294002/cAMP still showed more robust expression, similar to 
HUVECs.   
Cyclic AMP can counteract alterations to gene expression caused by NOTCH inhibition  
 We next sought to establish the effects on CXCR4 expression as well as arterial gene 
transcription in the presence of DAPT.  Given the ability of this compound to inhibit notch 
signaling, we theorized that this would diminish the expression of key arterial components that 
were being analyzed.  HUAECs and H9-derived ECs showed similar decreases in CXCR4 surface 
expression compared to untreated controls whereas HUVECs actually showed a slight increase 
that was dose-dependent (Fig. 10A).  Treatment with cAMP alone showed the expected increase 
in expression but concurrent treatment with DAPT again showed dose-dependent decreases in 
HUAECs and H9-derived ECs alongside increases in HUVECs.  Gene expression data shows that 
HUAEC Cxcr4 transcription is indeed slightly diminished in the presence of DAPT without 
cAMP while DAPT and cAMP treatments show increased transcription with dose-dependent 
decreases (Fig. 10B). H9-EC gene expression data shows a similar trend albeit with a lower 
increase in magnitude (Fig. 10C).  HUVEC results show slight increases in the DAPT only 
treatments, but show dose-dependent decreases to Cxcr4 transcription that are similar to HUAEC 
and H9-EC which does not follow the trend seen in the flow cytometry data (Fig. 10D).  
Interestingly, HUAECs treated with 1µM and 5µM DAPT resulted in significant increases in 
Notch1 expression along with less pronounced increases in Dll1 and Jag1 (Fig. 10E).  Even 
further increases in expression were seen in the 1µM DAPT/cAMP samples but the 5µM 
DAPT/cAMP showed a significant decrease in Notch1 transcription although the levels were still 
above the untreated control.  HUVECs showed a similar trend of increased transcription of 
Notch1 in the presence of DAPT only with diminished expression when cAMP was included 
(Fig. 10F).  H9-ECs did not show increased transcription of Notch1 when treated with 5µM 
DAPT which we saw in HUVECs and HUAECs and also did not respond similarly in the 
presence of cAMP (Fig. 10E). 
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Figure 9. Arterial gene expression varies following treatment with LY294002 
and/or cAMP.  Gene expression analysis of arterial genes Notch1, Dll1, and 
Jagged1 in (A) HUAECs, (B) HUVECs, and (C) H9-ECs following 
LY294002/cAMP treatment for 24 hours.  Each set of data is standardized to 
untreated controls.  
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Figure 10. Notch inhibition limits CXCR4 expression but can increase 
Notch1 transcription. (A) Analysis of CXCR4 expression following 
treatment for 24 hours with 0μM, 1μM, or 5μM DAPT as well as with the 
addition of 0.5mM 8-Br-cAMP to each.  (B) qRT-PCR analysis of Cxcr4, 
CoupT-FII, and Prox1 expression in HUAECs after DAPT/cAMP treatment 
compared to untreated controls. 
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Figure 10. Gene expression of Cxcr4, CoupT-FII, and Prox1 in (C) H9-ECs 
and (D) HUVECs following DAPT/cAMP treatment for 24 hours.   
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Figure 10. Gene analysis of arterial genes Notch-1, Dll-1, and Jagged-1 in 
(E) HUAEC, (F) HUVEC, and (G) H9-ECs following DAPT/cAMP 
treatment. 
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Discussion 
 As mentioned, the goal of this study was twofold:  first, to enhance and optimize our 
differentiation protocol by identifying a defined media that would increase the development of 
mature endothelial cells and secondly to analyze the type of EC which resulted from this process 
and identify ways to increase arterial commitment.  Our initial methods of differentiation suffered 
from ambiguity in that the variety of cytokines present in the serum-containing media caused 
proliferation of multiple cell types of various lineages.  While we were still able to identify and 
isolate ECs from this mixture, it was difficult, inefficient, and time consuming.  Separation of the 
desired cells from the culture as a whole was also made difficult by the limitations of the MACS 
systems we used as the overwhelmingly large population of pre-sort cells presumably decreased 
the ability of the magnetic antibodies to isolate single cells from any aggregates that would form 
during collection.  We made efforts to only sort cell concentrations that fell within the 
manufacturer's specified ranges but the nature of the cell to cell adhesion of the cultures made 
truly single cell suspensions difficult to achieve.  These cultures where characterized by large 
swaths of fibroblast/mesenchymal-like tissue which also seemingly contained a high 
concentration of extracellular matrix proteins making enzymatic dissociation complicated.  The 
switch to a media containing defined cytokines helped to limit the overgrowth of these types of 
cells and the hematopoietic/vascular cells present were seemingly not as dependent on them for 
growth and expansion.  Our initial analyses involved using the defined media with pluripotent 
cultures in a feeder-free system on various substrates such as matrigel or fibronectin (data not 
shown). While we saw better development of cells expressing EC markers, these cultures were 
still characterized by some overgrowth of the fibroblast/mesenchymal cell types which continued 
to limit the efficiency of isolating the desired cells.  By switching to the spin EB system for 
differentiation, we saw a dramatic decrease in these types of cells which not only made sorting 
easier, but also reduced the amount of time needed for differentiation. 
 Having greatly enhanced the efficiency of our differentiation protocol, we needed to then 
ensure that we were not only developing cells that expressed the endothelial markers we desired 
but also that they would maintain endothelial phenotype and function for extended periods of 
time.  The largest and most persisting difficulty of this project was that sorted cell cultures that 
exhibited a genuine endothelial phenotype initially would "transform" into a more mesenchymal 
phenotype after a few passages.  We are still unsure of the exact nature of this event, but we 
suspect that there are a few potential reasons for it.  The process of endothelial-to-mesenchymal 
transition has been only recently identified and is still not entirely understood.  Studies have 
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shown, however, that it is an event that occurs during cardiac development as endothelial cells 
migrate and transform into mesenchymal cells which form the mitral and tricuspid valves in the 
heart as well as the septum
83,84
.  Another recent study by Igor Sluvkin's group at the University of 
Wisconsin found that mesenchymal cells differentiated in culture originated from an APLNR
+
 
precursor that was also characterized by angiogenic capabilities
85
.  To this end, we also theorize 
that the cells we sort for may not be fully committed to a mature endothelial phenotype and are 
undergoing additional differentiation when they are cultured in our standard endothelial 
conditions.  One way of addressing this would be to sort for multiple markers through use of 
fluorescent-activated cell sorting (FACS).  Analysis of cells sorted only for CD31 following spin 
EB differentiation reveal that there are distinct populations with varied expression of secondary 
markers such as CD43, CD144, and Flk1.  Even up to two weeks post-sort, non-adherent cells 
that are collected and analyzed express early hematopoietic markers such as CD43 and CD45 
(data not shown).  It is unknown at this point what effect these differing populations have on the 
long-term viability of the ECs in culture.  Considering that our differentiation protocol is capable 
of inducing hematopoietic differentiation, it stands to reason that a portion of our CD31
+
 sorted 
cells are committed to or are in the process of committing to this lineage.  One final reason for 
deficiency in proliferation and  maintenance of an endothelial phenotype in sorted cells may be 
the lack of cell to cell interactions.  This situation mostly applies to our earlier studies with 
stromal cell co-culture methods as low yields of sorted cells would result in sparse density in the 
standard endothelial conditions culture.  EC cultures are defined by tight intercellular junctions so 
the lack of these may have detrimental effects on the ability of these cells to proliferate and 
adhere to an endothelial phenotype.  Whatever the case, we continue to try and understand this 
process and, in doing so, hope to find ways to limit this transition in order to maintain mature 
endothelial cells.  
 In our efforts to induce further endothelial commitment and differentiation, we have 
examined and continue to assess the effects of various growth factors and small molecule 
inhibitors.  The addition of APLN to differentiation cultures has shown a clear increase in certain 
endothelial markers, but has not provided any clearly evident benefit to long-term endothelial 
maintenance.  It is also unclear what effect this polypeptide has on commitment to a venous 
endothelial sub-type as opposed to arterial commitment.  As mentioned, activation of the apelin 
receptor, APJ, has been shown to be involved in not only vascular development as a whole but 
also commitment to the venous phenotype.  We do not know the true extent of this process in our 
in vitro system and further experiments are needed to determine whether the benefits to 
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endothelial development outweigh any decrease in ability to adopt an arterial phenotype.  The 
same is true for our use of the small molecule notch inhibitor DAPT as we are unsure of the long 
term effects on endothelial identity following treatment during differentiation.  While notch 
signaling has been shown to be essential for arterial development, these conclusions were drawn 
from studies using knockout mouse models.  Our use of DAPT in in vitro differentiation cultures 
may represent a more transient inhibition of notch signaling as it is only introduced into the media 
on day four.  It is unknown how persistent and effective it is at signal inhibition during the 
remaining three days of the differentiation.  Also, our use of DAPT treatment in primary cells and 
sorted ECs was only analyzed following treatment for 24 hours so it would be of interest to 
examine the effects of longer exposure to the inhibitor.  There is no known in vitro assay to assess 
functional differences between venous and arterial cells so it is difficult to determine the effects 
of this treatment outside of phenotypic differences.  The use of cAMP and PI3K inhibitor assays 
was also limited to more mature cells so we are unsure of the effects these would have on 
differentiating cells and their expression of arterial markers and genes.  More extensive analysis 
of the effects of these assays would be beneficial considering the variety of signaling processes 
that these two pathways interact with.  Also of interest would be the long term gene expression 
modification that these assays may or may not affect.   
 While inhibition of PI3K did not show robust increases across the board of arterial-
specific genes, there is clearly a positive dose-dependent response in CXCR4 expression which 
can be further enhanced in the presence of cAMP.  We have not yet identified the exact nature of 
this mechanism or the potential benefits it may have for use in the cardiac ischemia models which 
leaves room for future examinations.  We also continue to experiment with alternative PI3K 
inhibitors, such as PI-103, which possess different capacities to bind and inhibit not only PI3K 
but also related signaling pathway kinases such as mTOR.  Long-term inhibition of these 
signaling kinases is not ideal as they are involved in important pathways that are responsible for 
cell survival and proliferation.  It would be of interest to compare the results of these assays with 
other forms of expression augmentation such as small interfering RNAs (siRNA) in order to 
determine the efficiency of each system.  Also of interest would be a more thorough analysis of 
the downstream effects of cAMP and PI3K inhibition.  This would be beneficial in determining 
whether the effects we see are the result of gene expression adjustment of CXCR4 or from some 
other process such as post-translational modification.  As we further elucidate the effects of this 
inhibition and the exact mechanisms of its action we hope to be able to further augment it in order 
to achieve effective conversion or enhancement of an arterial phenotype in differentiated ECs.  
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Conversely, we have yet to identify or experiment with methods of inhibiting COUP-TFII or 
other effectors which are critical for development of the venous endothelial phenotype.  We are 
unaware of any small molecule inhibitors like DAPT that are capable of efficiently targeting and 
disrupting COUP-TFII signaling so inhibition assays at this point would require genetic knockout 
or knockdown of COUP-TFII transcripts.  Gene analysis of differentiating cells in our spin EB 
system could be used to identify the temporal expression of those genes which are involved in the 
arterial-venous specification and would be essential for determining the most ideal time points for 
inhibition/activation in order to drive arterial commitment.  
 Given the difficulties of isolating and maintaining endothelial cells derived from 
pluripotent stem cells in culture, it has been encouraging to see the results from our feeder-free 
system using a defined differentiation media.  It is still not perfect but has allowed us to grow 
large numbers of these cells for experimental use compared to the stromal cell co-culture method 
that was originally used.  We continue to refine this process in order to develop a more reliable 
system that can be faithfully replicated by us and others who may desire to use it.  We are also 
encouraged by the results obtained from our experiments regarding arterial commitment and 
persist in optimizing them in order to truly understand the cellular processes involved.  The hope 
is that this research can be used to further the understanding of endothelial development and 
potentially for future cellular therapies that would be beneficial for treatment of cardiovascular 
disorders and disease. 
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